Drugs / EBARESDAX
EBARESDAX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05008835 | Jul 2021 → Oct 2022 | osteoarthritis, knee | ACADIA Pharmaceuticals Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04855240 | Mar 2021 → Feb 2022 | — | ACADIA Pharmaceuticals Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | ACADIA Pharmaceuticals Inc. | Results Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain acadia.com ↗
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-18 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain acadia.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBARESDAX | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095417 ↗ |
| Known as | ACP-044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008835 ↗ |
| Known as | ACP-044 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095417 ↗ |
| Known as | EBARESDAX HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095417 ↗ |
| Modality | Small molecule | — CHEMBL5095417 ↗ |
| Route | Oral | “Oral dose of ACP-044 Dose A” NCT04855240 ↗ |